Each year, approximately 400,000 out-of-hospital cardiac arrests occur in the United States ([@bib1],[@bib2]). Of these, approximately only 5% to 10% achieve neurologically intact survival ([@bib3]). Approximately one-third of patients experiencing out-of-hospital cardiac arrests present with ventricular tachycardia/ventricular fibrillation (VF) ([@bib4]). Epinephrine is a commonly used vasoconstrictor for standard cardiopulmonary resuscitation (CPR) in and out of hospital protocols in congruence with current American Heart Association guidelines; however, no study to date has shown improvement in long-term outcomes ([@bib5]).

A new method of CPR has been proposed that significantly increases forward blood flow and overall patient outcomes ([@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11]). Sodium nitroprusside--enhanced CPR (SNPeCPR) is the combination of 3 basic components: 1) SNP, a potent vasodilator, to decrease peripheral vascular resistance in tandem with abdominal binding ([@bib7],[@bib8]) to decrease descending aorta runoff and redirect blood flow to the vital organs; 2) an impedance threshold device; and 3) active compression/decompression CPR to actively increase venous return ([@bib11]). Together, these components act synergistically to increase coronary and cerebral perfusion during CPR ([@bib12]).

Previous studies of SNPeCPR have indicated an improved carotid blood flow (CBF), end-tidal CO~2~, and return of spontaneous circulation (ROSC) rates and short-term 24- to 48-h survival rates with favorable neurologic function compared to those of standard CPR ([@bib8],[@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]). There appears to be a vital timepoint after which hemodynamic decompensation during extended standard CPR is inevitable and irreversible ([@bib19]). The use of SNPeCPR shifts the survival curve, increasing a valuable window for which to resuscitate the patient ([@bib8],[@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]). This shift of the metabolic wall represents an invaluable clinical application of patient selection for furthered resuscitation efforts. As more patients are treated following prolonged periods of CPR, and with increasing access to enhanced CPR (eCPR) and veno-arterial extracorporeal membrane oxygenation therapies, providing a superior advanced cardiac life support (ACLS) and CPR method will become critical ([@bib20]). Before the first clinical trial for SNPeCPR can be performed, safety must be further evaluated.

We sought to investigate the blood flow effects of SNPeCPR during prolonged CPR and to understand the predominant mechanism of its action. We hypothesized that the predominant effect of SNPeCPR is indiscriminate profound pulmonary vasodilation. As such, the ability to maintain adequate oxygenation with SNPeCPR was the main focus of this study.

Methods {#sec1}
=======

All studies were performed with approval from the Institutional Animal Care and Use Committee. Animal care was compliant with the National Research Council's Guide of 1996 for the Care and Use of Laboratory Animals (protocol number 1802-35586A)([@bib21]).

Animal model {#sec1.1}
------------

We used 25 Yorkshire pigs with an average weight of 51.5 ± 1.4 kg. Twelve animals were randomized to receive SNPeCPR and 13 to receive standard CPR. The surgical preparation, anesthesia, and data monitoring have been described thoroughly in previous studies ([@bib7],[@bib22]). Intramuscular ketamine and xylazine was provided as sedation (5 ml of 100 mg/ml dose and 1 to 3 mg/kg, respectively). This was followed by inhaled isoflurane at a dose of 1% to 1.4%. Endotracheal intubation was performed with a 7.5-mm endotracheal tube. Animals were ventilated with a tidal volume of 10 ml/kg using room air volume control ventilation (Narkomed, Draeger Medical, Telford, Pennsylvania). The respiratory rate was adjusted to maintain partial pressure of carbon dioxide (PaCO~2~) of 40 mm Hg as measured by arterial blood (Gem 3500, Instrumentation Laboratory, Bedford, Massachusetts). Arterial blood gases were obtained at baseline and every 5 min until 30 min of CPR. Animal temperature was measured with an esophageal temperature probe and normothermia (37 ± 0.5 ºC) was maintained with convective warming unit (Covidien Warm Touch, Mansfield, Massachusetts). Vascular access was obtained in the femoral artery and the right external jugular vein percutaneously using ultrasound guidance with an 8-F and 6-F catheter, respectively. The central aortic blood pressure was measured with a Millar catheter (Millar Instruments, Houston, Texas) placed in the descending thoracic aorta. The right atrial pressure was also measured with a Millar catheter that was inserted via the right external jugular sheath. The measurements from these Millar catheters were used for calculation of coronary perfusion pressure as the difference between diastolic blood pressure and right atrial pressure in spontaneous circulation, and the difference between decompression phase arterial pressure and the right atrial pressure at maximal decompression during the arrest. Both sheaths were placed percutaneously with an ultrasound-guided Seldinger technique. The left common carotid artery was surgically exposed and a Doppler flow probe (Transonic, 400-Series Multi-channel, Transonic Systems Inc. Ithaca, New York) was placed around it to quantify the CBF. All animals received a 5,000-U intravenous bolus of heparin upon completion of surgical access. Hemodynamic data were continuously recorded (Labview 2015, National Instruments, Austin, Texas). Electrocardiograms were continuously recorded, as well as end-tidal CO~2~, tidal volume, minute ventilation, and blood oxygen saturation (Cardiocap/5, Datex-Ohmeda, Louisville, Colorado).

Experimental protocol {#sec1.2}
---------------------

Following the aforementioned surgical preparation, baseline values were recorded. The timeline for the experimental protocol is outlined in [Figure 1](#fig1){ref-type="fig"}. VF was electrically induced in all animals with a pacing wire inserted through the right jugular vein sheath into the right ventricle. Upon inducing VF, mechanical ventilation was suspended. VF was left untreated for 3.5 min to mimic an arrival time for first responders*.* After untreated VF, basic life support (BLS) with active decompression (ACD) and an impedance threshold device (ITD) (ACD + ITD) and mechanical ventilations at a rate of 10 respirations per minute was initiated for all animals. The mechanical CPR parameters were held constant: compression/decompression duty cycle of 50%, rate of 100 compressions per minute, and target depth of 20% of the anteroposterior diameter. Mechanical ACD + ITD CPR was used for all animals to optimize perfusion during BLS ([@bib6]). BLS was performed for 10 min to simulate the time required for arrival of ACLS providers.Figure 1Study ProtocolACLS = advanced cardiac life support; admin = administration (of); BLS = basic life support; CPR = cardiopulmonary resuscitation; DC = decompression; ISO = isoflurane; ROSC = return of spontaneous circulation; SNPeCPR = sodium nitroprusside--enhanced cardiopulmonary resuscitation; VF = ventricular fibrillation; q5 min = every 5 min.

Following 10 min of BLS, animals were randomized to either SNPeCPR or standard ACLS CPR groups.

### SNPeCPR group {#sec1.2.1}

SNPeCPR added manual abdominal binding on the ongoing mechanical ACD + ITD CPR and SNP 1mg intravenous bolus every 5 min as previously described ([@bib7]).

### Standard ACLS group {#sec1.2.2}

The standard ACLS group continued to receive ACD + ITD CPR (similar to BLS) and received epinephrine 0.5 mg intravenous bolus every 5 min starting at minute 10 ([@bib6]).

At 28 min of total CPR, all animals were administered 25 mg amiodarone and 50 mEq bicarbonate. At the 30-min CPR mark, animals were defibrillated with 200-J biphasic shocks. Shocks were performed every 2 to 3 min for an additional 15 min at which point efforts were terminated if no ROSC was achieved. Animals with ROSC were followed for a total of 60 min, at which point they were sacrificed.

Ventilation, oxygen delivery strategy, and alveolar-arterial gradient calculation {#sec1.3}
---------------------------------------------------------------------------------

All animals were ventilated as stated above at 10 breaths per minute with 10 ml/kg tidal volume. Room air was used during preparation and at the initiation of the VF. During CPR, oxygen was increased only if a saturation of \<90% was observed (as indicated by arterial blood gas \[ABG\] values taken at 5-min intervals). Fraction of inspired oxygen (FiO~2)~ was recorded and adjusted incrementally by ∼25%, only enough to increase the O~2~ saturation above 90%. After the FiO~2~ adjustment, the alveolar-arterial (A-a) gradient was calculated based on the recorded Fi0~2~ and the arterial partial pressure of oxygen (PaO~2~) standard formula at the next ABG reading:$$\text{A} - \text{a}\text{~Gradient} = \left( {F_{i}O_{2}\left( {P_{atm} - P_{H_{2}O}} \right) - \frac{P_{a}CO_{2}}{0.8}} \right) - P_{a}O_{2}$$

As such, the study sought to evaluate both the effect of SNPeCPR on pulmonary vasodilation but also the level of FiO~2~ support needed to maintain adequate tissue oxygenation over time.

Statistical analysis {#sec1.4}
--------------------

All statistics were compiled using GraphPad Prism 6 software (GraphPad Software, La Jolla, California). All values are expressed as means ± SEM and categorical data as fractions. An unequal variance Student *t* test was utilized to analyze statistical differences in the hemodynamic and blood gas data. Two-way analysis of variance tests were used to evaluate treatment, time effects on lactic acid, and A-a gradient data; and Scheffe's method was used for alpha-adjustment. A p value \<0.05 was considered statistically significant. An additional random effect model analysis was completed in R studio (R development core team, 2018) to assess the effects of time to the value of lactate in the different treatment groups. The Fisher exact test was performed to assess the ROSC rates at the end of prolonged CPR. A Kaplan-Meier curve was constructed to assess the rate of decrease in coronary perfusion pressure over time between the 2 different groups. Log-rank test was used to assess the equality of the curves.

Results {#sec2}
=======

Survival {#sec2.1}
--------

All animals randomized received at least 30 min of CPR. The ROSC rate was significantly higher for SNPeCPR animals (9 of 12 \[75%\]) compared to standard ACLS animals (3 of 13 \[23%\]) (p = 0.017). ROSC efforts were continued for up to 15 min after completion of the 30-min CPR protocol. All animals that achieved ROSC survived for the full 1-h observation period.

Hemodynamics {#sec2.2}
------------

Use of SNPeCPR maintained higher systemic perfusion and minimized ischemia as observed through slower rise of lactic acid during prolonged CPR ([Figure 2](#fig2){ref-type="fig"}). Furthermore, use of SNPeCPR increased coronary perfusion pressure (p \< 0.001) and CBF (p = 0.002) ([Table 1](#tbl1){ref-type="table"}). The hemodynamic effects of SNPeCPR were immediate and seen within the first 5 min after the first injection at minute 10 of CPR ([Figure 1](#fig1){ref-type="fig"}). Moreover, SNP animals had significantly higher diastolic blood pressure (p = 0.021), whereas no difference was observed between systolic blood pressure in the 2 groups (p = 0.394).Figure 2Hemodynamic Comparison of SNP and Epinephrine During CPR**(A)** Coronary perfusion pressure **(B)**, lactate, **(C)** carotid flow, and **(D)** aortic pressure over the 30 min of cardiopulmonary resuscitation (CPR). All parameters except systolic blood pressure are statistically significant between treatment groups after the 20-min CPR time mark. The 10-min CPR directly precedes intervention of sodium nitroprusside (SNP) or epinephrine administration. Lactate p value for treatment is 0.003. p values for coronary perfusion pressure, carotid flow, systolic aortic pressure, and diastolic aortic pressure on relaxation were \<0.001, 0.002, 0.394, and 0.021, respectively. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001. BL = basic life; CPP = coronary perfusion pressure; other abbreviations as in [Figure 1](#fig1){ref-type="fig"}.Table 1Hemodynamic Data at Baseline and at 5-Min Intervals During 30 Min of CPRTimeTreatmentRA Pressure, mm HgCompression RA Pressure, mm HgSBP, mm HgDBP, mm HgCPP, mm Hg%CBFBLSNPeCPR5 ± 0.9Not applicable111 ± 17.076 ± 13.671 ± 12.7100 ± 0Standard ACLS CPR4 ± 0.4Not applicable107 ± 15.572 ± 13.068 ± 8.9100 ± 05 minSNPeCPR7 ± 1.172 ± 8.973 ± 9.328 ± 6.521 ± 5.825 ± 5.5Standard ACLS CPR8 ± 2.365 ± 18.864 ± 19.726 ± 5.218 ± 5.824 ± 10.810 min[∗](#tbl1fnlowast){ref-type="table-fn"}SNPeCPR6 ± 1.768 ± 10.569 ± 11.128 ± 5.122 ± 5.622 ± 4.5Standard ACLS CPR8 ± 2.765 ± 2264 ± 21.427 ± 10.019 ± 6.426 ± 12.115 minSNPeCPR7 ± 2.163 ± 10.864 ± 10.031 ± 9.224 ± 5.0[†](#tbl1fndagger){ref-type="table-fn"}30 ± 10.0[†](#tbl1fndagger){ref-type="table-fn"}Standard ACLS CPR6 ± 1.669 ± 20.668 ± 21.425 ± 9.819 ± 7.1[†](#tbl1fndagger){ref-type="table-fn"}23 ± 2.0[†](#tbl1fndagger){ref-type="table-fn"}20 minSNPeCPR5 ± 2.961 ± 14.263 ± 13.730 ± 11.625 ± 6.0[†](#tbl1fndagger){ref-type="table-fn"}30 ± 11.1[†](#tbl1fndagger){ref-type="table-fn"}Standard ACLS CPR6 ± 3.166 ± 20.967 ± 22.523 ± 10.217 ± 5.6[†](#tbl1fndagger){ref-type="table-fn"}21 ± 4.4[†](#tbl1fndagger){ref-type="table-fn"}25 minSNPeCPR6 ± 3.260 ± 18.259 ± 17.730 ± 11.1[†](#tbl1fndagger){ref-type="table-fn"}24 ± 7.5[†](#tbl1fndagger){ref-type="table-fn"}31 ± 14.1[†](#tbl1fndagger){ref-type="table-fn"}Standard ACLS CPR4 ± 1.858 ± 17.359 ± 17.620 ± 5.7[†](#tbl1fndagger){ref-type="table-fn"}16 ± 6.1[†](#tbl1fndagger){ref-type="table-fn"}17 ± 1.7[†](#tbl1fndagger){ref-type="table-fn"}30 minSNPeCPR10 ± 6.559 ± 23.958 ± 25.230 ± 13.1[†](#tbl1fndagger){ref-type="table-fn"}20 ± 11.7[†](#tbl1fndagger){ref-type="table-fn"}24 ± 8.1[†](#tbl1fndagger){ref-type="table-fn"}Standard ACLS CPR3 ± 0.657 ± 17.856 ± 19.517 ± 5.2[†](#tbl1fndagger){ref-type="table-fn"}14 ± 4.6[†](#tbl1fndagger){ref-type="table-fn"}18 ± 3.1[†](#tbl1fndagger){ref-type="table-fn"}[^1][^2][^3][^4]

ABGs {#sec2.3}
----

Arterial and venous blood gas results over the entire 30 min of prolonged CPR are shown in [Table 2](#tbl2){ref-type="table"}. SNPeCPR showed a significant decrease in PaO~2~ levels after SNP delivery which coincided with an increased A-a gradient. Increasing the FiO~2~ led to adequate PaO~2~ and overall tissue oxygen delivery while the increase in circulating blood flow induced by SNP infusion was maintained. The higher normal mixed venous oxygen tension (PvO~2~) in the SNPeCPR animals suggests increased tissue perfusion and oxygen delivery. The lower arteriovenous proportion of SO~2~ difference further suggests adequate oxygen delivery in agreement with the higher blood flow markers and perfusion pressures ([Figure 3](#fig3){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}).Table 2Arterial and Venous Blood Gas Results at Baseline and at 5-Min Intervals During 30 Min of CPRTimeTreatmentpHPaCO~2~PaO2PvO2LacFiO~2~BLSNPeCPR7.48 ± 0.0638 ± 7.6113 ± 1746 ± 31.0 ± 0.40.25 ± 0.017Standard ACLS CPR7.5 ± 0.0441 ± 3.8106 ± 2044 ± 7.30.8 ± 0.20.26 ± 0.0245 minSNPeCPR7.44 ± 0.0830 ± 5.096 ± 17.529 ± 5.63.9 ± 1.10.25 ± 0.017Standard ACLS CPR7.43 ± 0.0732 ± 5.7103 ± 15.028 ± 7.54.2 ± 0.80.26 ± 0.01610 min[∗](#tbl2fnlowast){ref-type="table-fn"}SNPeCPR7.39 ± 0.0429 ± 3.098 ± 18.426 ± 3.35.1 ± 1.50.26 ± 0.016Standard ACLS CPR7.39 ± 0.0531 ± 4.9102 ± 14.426 ± 85.3 ± 0.90.26 ± 0.01615 minSNPeCPR7.36 ± 0.0632 ± 3.667 ± 13.9[†](#tbl2fndagger){ref-type="table-fn"}28 ± 5.56.0 ± 1.70.26 ± 0.025Standard ACLS CPR7.37 ± 0.0529 ± 5.094 ± 17.723 ± 5.36.3 ± 1.10.26 ± 0.01520 minSNPeCPR7.33 ± 0.0834 ± 8.1[†](#tbl2fndagger){ref-type="table-fn"}68 ± 18.1[†](#tbl2fndagger){ref-type="table-fn"}29 ± 7.2[†](#tbl2fndagger){ref-type="table-fn"}6.6 ± 2.10.43 ± 0.23[†](#tbl2fndagger){ref-type="table-fn"}Standard ACLS CPR7.35 ± 0.0626 ± 5.495 ± 17.421 ± 8.5[†](#tbl2fndagger){ref-type="table-fn"}7.4 ± 1.10.26 ± 0.01625 minSNPeCPR7.33 ± 0.1537 ± 11.2[†](#tbl2fndagger){ref-type="table-fn"}64 ± 11.5[†](#tbl2fndagger){ref-type="table-fn"}26 ± 7.47.2 ± 2.3[†](#tbl2fndagger){ref-type="table-fn"}0.56 ± 0.31[†](#tbl2fndagger){ref-type="table-fn"}Standard ACLS CPR7.32 ± 0.0626 ± 5.993 ± 16.720 ± 11.48.7 ± 1.1[†](#tbl2fndagger){ref-type="table-fn"}0.26 ± 0.01630 minSNPeCPR7.39 ± 0.1351 ± 21.853 ± 14[†](#tbl2fndagger){ref-type="table-fn"}26.4 ± 6.58.2 ± 2.5[†](#tbl2fndagger){ref-type="table-fn"}0.58 ± 0.31[†](#tbl2fndagger){ref-type="table-fn"}Standard ACLS CPR7.37 ± 0.2139 ± 2077 ± 24.4[†](#tbl2fndagger){ref-type="table-fn"}21 ± 6.010.0 ± 1.5[†](#tbl2fndagger){ref-type="table-fn"}0.27 ± 0.037[^5][^6][^7][^8]Figure 3Blood Oxygenation Comparison Between SNP and Epinephrine During CPRAlveolar-arterial (A-a) gradient **(A)** and arteriovenous oxygenation gradient **(B)** over the 30 min of CPR. All parameters are statistically significant between treatment groups after the 20-min CPR time mark. A-a gradient values are unitless. The 10-min CPR directly precedes intervention of SNP or epinephrine administration. The p values of treatment for A-a gradient and arteriovenous oxygenation gradient is \<0.001 and 0.004, respectively. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001. Abbreviations as in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}.

A coronary perfusion pressure of \<15 mm Hg has been negatively associated with achieving ROSC and successful defibrillation ([@bib23],[@bib24]). SNPeCPR animals fell below this threshold later than compared to control animals ([Table 1](#tbl1){ref-type="table"}, [Figure 4](#fig4){ref-type="fig"}). As it can be seen in the Kaplan-Meier plot ([Figure 4](#fig4){ref-type="fig"}), animals reaching of coronary perfusion pressure (CPP) \<15 mm Hg are significantly delayed in the SNPeCPR cohort (p = 0.047).Figure 4CPP-Guided Survival FunctionKaplan-Meier curve for the time until coronary perfusion pressure (CPP) \< 15 mm Hg within the SNPeCPR and standard CPR cohorts. Our data suggest that after 20 min of CPR (within 10 min of ACLS initiation). CPP drops below 15 mm Hg much faster in the standard CPR cohort. CPp \< 15 mm Hg has been adversely related to achieving ROSC ([@bib23]). SNPeCPR delays the decay of CPP to below ROSC threshold. sCPR = standard cardiopulmonary resuscitation; other abbreviations as in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}.

Discussion {#sec3}
==========

SNPeCPR increased the cardiac output generated by chest compressions resulting in increased CPP and CBF and decreased lactic acid levels when compared to standard ACLS. SNP is the most potent vasodilator available with potent dilatory effects in both the arterial and venous circulation, including the pulmonary vasculature ([@bib25],[@bib26]). This study has shown that pulmonary arterial vasodilation was an important mechanism of the positive hemodynamic effects of SNPeCPR. The 6-fold increase in A-a gradient suggested a substantial increase in transpulmonary flow resulting in increased left ventricular preload and increased cardiac output. Importantly, in the setting of prolonged CPR, the increased cardiac output and resulting increase in diastolic blood pressure provided by SNPeCPR prolonged the duration of ROSC-compatible hemodynamics by maintaining the CPP needed to achieve ROSC ([@bib27]). This allowed for higher ROSC rates after 30 min of prolonged CPR and higher survival rates with ongoing observation ([@bib7],[@bib8],[@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]).

The observed 6-fold increase in A-a gradient in the SNPeCPR group showed a substantial increase in pulmonary shunt due to increased transpulmonary blood flow. Profound pulmonary vasodilation induced by SNP increases perfusion throughout the pulmonary vasculature. This reversal of hypoxemic vasoconstriction and increased perfusion to nonventilated alveoli increased shunt physiology, thereby decreasing arterial oxygen content. In SNPeCPR animals, oxygen saturation of \<90% was reversed by increasing FiO~2~ in 25% increments all the way up to 1.0, if needed, over the 20 min of ACLS. A moderate increase in FiO~2~ to 0.5 was adequate in the majority of the SNPeCPR treated animals to keep saturation above 90% to 92%. While arterial oxygen saturation was reduced, total oxygen delivery to tissues was maintained or even increased with SNPeCPR due to increased cardiac output. This was shown by the simultaneous increase in A-a gradient and decrease in PaO~2~ levels in association with lower lactic acid levels and similar mixed venous oxygen levels. Stable oxygen delivery despite decreased PaO~2~ levels suggested higher perfusion in agreement with the increased CPP and CBF.

The requirement for increased FiO~2~ did not compromise the outcomes in the SNPeCPR cohort as supported by the resuscitation rates between the 2 groups. CPR is a low-flow state, and the impact of high arterial oxygen levels on outcomes is poorly understood. In our study, although the SNPeCPR group had lower PaO~2~ and relative hypoxemia, tissue oxygen consumption was improved due to the increase in CPR-generated blood flow; therefore, there was no evidence of worsening tissue hypoxia compared to standard ACLS. The clinical effect of SNPeCPR, with the need for a higher FiO~2~, on neurological intact survival in humans can be only assessed with a clinical trial after safety has been documented in a Phase 1 trial.

SNPeCPR increased CBF immediately upon injection which was maintained throughout the 30 min of CPR performed in this study ([@bib12]). Similar increases in CPP were also seen although coronary blood flow was not directly measured. It remains unknown if increases in CBF were due to SNP-induced vasodilation of cerebral vasculature or simply a manifestation of the increased cardiac output and arterial blood pressure caused by SNP combined with external carotid vasodilation. In addition, SNPeCPR animals appeared to have a higher PaCO~2~, most likely related to large ventilation perfusion mismatch. Although shunting immediately affects PaO~2~, PaCO~2~ does not begin to increase until shunt reaches or exceeds 50% ([@bib28]). The combination of direct vasodilation and increased PaCO~2~ may contribute to an increase of cerebral blood flow. The consistently observed increase in CBF with SNPeCPR may be associated with the improved neurologic outcomes that have been reported in previous publications ([@bib8],[@bib12],[@bib14],[@bib15],[@bib17]).

Prolonged CPR leads to death by progressive accumulation of tissue oxygen debt, ischemic injury, and cell death. As such, treatments meant to prolong patient viability during resuscitation should target this detrimental progression to increase the potential for ROSC and thereby limit brain ischemia and anoxic injury following prolonged periods of CPR. SNPeCPR extended ROSC potential and patient viability as shown by the slower accumulation of arterial lactic acid and preservation of CPP and CBF compared to that of control animals. Lactic acid is a reliable and reproducible indicator of tissue hypoxia that has been directly correlated with mortality ([@bib29]) and poor neurologic outcomes ([@bib30]). The slower rate of lactic acid accumulation in the SNPeCPR group indicates improved tissue oxygenation and, along with the preservation of CPP, supports an increase in the duration of patient viability and potential for ROSC ([@bib31]). In recent studies, only 2.3% of patients receiving CPR longer than 30 min achieved ROSC ([@bib32], [@bib33], [@bib34], [@bib35], [@bib36]). In contrast, this study has shown an ROSC rate of 75% with 30 min of CPR in pigs receiving SNPeCPR. In the setting of refractory VF, prolonged CPR may be particularly critical as patients are often transported to an eCPR-capable hospital. Transport may require additional time. Prolonged patient viability with SNPeCPR would be hypothesized to improve patient outcomes in this setting.

Study limitations {#sec3.1}
-----------------

This study has multiple limitations. Although our study was designed to mimic the clinical reality of patients suffering refractory out-of-hospital VF cardiac arrest, unavoidable discrepancies persist. First, the animal model may have limited translatability to humans due to the relatively young age of the pigs and lack of coronary artery atherosclerosis and cardiovascular comorbidities such as diabetes. Second, during the ACLS phase, our study model provided no defibrillations to maintain the extended CPR model. Therefore, we cannot accurately assess the ability of SNPeCPR or control treatment to facilitate ROSC before 30 min of CPR. Furthermore, this leads to inclusion of all animals in the prolonged CPR group. This may also lead to inclusion of animals with more severe systemic injury that would have otherwise achieved ROSC early which would be expected to minimize differences between groups and minimize the observed relative effect of SNPeCPR. The use of anesthesia, as required for animal studies, may also limit the observed differences between groups as inhaled anesthetics such as isoflurane used in this study can provide cardioprotective effects. Moreover, the pulmonary vascular resistance was calculated indirectly and in the absence of direct assessment of cardiac output due to the inaccuracy of measurements in cardiac arrest due to significant motion artifact and the extreme low blood flow. Finally, we did not thoroughly examine the dose-dependent effects of SNP, but we have based the dosing on previously published studies where it was correlated with positive clinically relevant outcomes.

Conclusions {#sec4}
===========

SNPeCPR improves vital organ blood flow and tissue oxygenation during prolonged resuscitation. This is predominantly achieved by a significant decrease in pulmonary artery resistance that leads to a substantial increase in the A-a oxygen gradient over time. However, tissue oxygen delivery is not compromised when FiO~2~ can be increased to compensate. Our results support the implementation of the first clinical trial of SNPeCPR in humans. It further informs us of the necessary use of the 100% oxygen ventilation strategy and hypoxia as the primary safety endpoints.Perspectives**COMPETENCY IN MEDICAL KNOWLEDGE:** SNPeCPR is a novel CPR method that uses an advanced mechanical CPR platform with SNP---a potent vasodilator---to improve vital organ flow. SNPeCPR causes peripheral systemic vasodilation and, as our study shows, a significant and profound pulmonary circulation vasodilation. SNPeCPR has been shown to increase ROSC rates and short-term neurologically intact survival rates in multiple studies and is ready for a phase 1 clinical trial.**TRANSLATIONAL OUTLOOK:** The current study identifies hypoxemia as a potential safety issue during ventilation with room air and suggests that SNPeCPR should be tested in humans with an FiO~2~ \>0.5. Despite relative hypoxemia with lower FiO~2~ ventilation, SNPeCPR oxygen delivery to the tissues is increased due to higher blood flow generation.
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[^1]: Values are mean ± SEM.

[^2]: ACLS = advanced cardiac life support; BL = baseline values; CBF = carotid blood flow; %CBF = proportion of CBF as a percent of the initial baseline value; CPP = coronary perfusion pressure; CPR = cardiopulmonary resuscitation; DBP = diastolic blood pressure; RA = right atrial; SBP = systolic blood pressure; SNPeCPR = sodium nitroprusside--enhanced cardiopulmonary resuscitation.

[^3]: The dividing line at 10 min indicates the initiation of randomization and drug administration.

[^4]: p \< 0.05.

[^5]: Values are mean ± SEM. All partial pressures are shown in mm Hg.

[^6]: FiO~2~ = fraction of inspired oxygen; Lac = lactate levels in mmol/l in arterial blood; PaCO~2~ = partial pressure of carbon dioxide in arterial blood; PaO~2~ = partial pressure of oxygen in arterial blood; PvO~2~ = partial pressure of oxygen in venous blood; other abbreviations as in [Table 1](#tbl1){ref-type="table"}.

[^7]: The dividing line at 10 min indicates the initiation of randomization and drug administration.

[^8]: p \< 0.05.
